Clinical Trials on Multiple Myeloma - Clinical Trials Registry - ICH GCP

Example: Heart Attack

Clinical Trials on Multiple Myeloma

Total 2665 results

NCT05444348

Recruiting

Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)

Conditions: Multiple Myeloma, Myelodysplastic Syndromes, Lymphoma, Acute Myeloid Leukemia
NCT04925193

Recruiting

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Conditions: Multiple Myeloma in Relapse
NCT04822337

Recruiting

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

Conditions: Multiple Myeloma
NCT04721002

Recruiting

Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)

Conditions: Multiple Myeloma (MM)
NCT04662099

Recruiting

T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma

Conditions: CS1+ or BCMA+ Multiple Myeloma
NCT02649790

Recruiting

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Conditions: Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS
NCT04113018

Active, not recruiting

Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

Conditions: Multiple Myeloma
NCT05432414

Recruiting

PVd Versus Vd in NDMM Patients With RI

Conditions: Multiple Myeloma
NCT04545333

Recruiting

The clonoSEQ® Watch Registry

Conditions: Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-hodgkin Lymphoma
NCT04414475

Recruiting

A Study of Selinexor Plus Low-dose Dexamethasone in Participants With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone in Participants With Triple-class Refractory Multiple Myeloma

Conditions: Multiple Myeloma, Refractory
NCT00898235

Recruiting

Collection of Samples and Clinical Data From Patients With Amyloid Diseases

Conditions: Multiple Myeloma
NCT05706766

Not yet recruiting

Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Conditions: Multiple Myeloma, Stem Cell Transplant Complications
NCT03773107

Active, not recruiting

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

Conditions: Multiple Myeloma
NCT02924272

Active, not recruiting

Ixazomib Rollover Study

Conditions: Multiple Myeloma, Lymphoma, Amyloidosis
NCT02886065

Active, not recruiting

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

Conditions: Smoldering Multiple Myeloma
NCT02343042

Active, not recruiting

Selinexor and Backbone Treatments of Multiple Myeloma Patients

Conditions: Multiple Myeloma
NCT01951885

Completed

Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention

Conditions: Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Hodgkins Disease, Chronic Lymphocytic Leukemia, Multiple Myeloma
NCT05652335

Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

Conditions: Relapsed or Refractory Multiple Myeloma
NCT05572515

Recruiting

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

Conditions: Relapsed or Refractory Multiple Myeloma
NCT05552222

Recruiting

A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma

Conditions: Multiple Myeloma
NCT05552976

Recruiting

A Study to Evaluate CC-92480 in Combination With Carfilzomib and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

Conditions: Relapsed or Refractory Multiple Myeloma
NCT05338775

Recruiting

A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

Conditions: Relapsed/ Refractory Multiple Myeloma
NCT05201781

Recruiting

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Conditions: Multiple Myeloma
NCT05160584

Recruiting

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

Conditions: Relapsed/Refractory Multiple Myeloma
NCT04923893

Recruiting

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

Conditions: Multiple Myeloma